(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CYTOGEN

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

CYTOGEN

ST13

US500000097489712

Class

5

Filing

97489712

Registration

7554638

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

25

Latest update

11/05/2024

Classification

Registered

Trademark type

Word

Nice classes

5

Filing date

07/05/2022

Registration date

11/05/2024

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/05/2024

Last transaction

11/05/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

4

Owner type

03

Owner location

Seoul, KR

Examiner

LAWRENCE, SUSAN KASTRINER

Law office

M70

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

Cytogen, Inc.

Representatives

Nazly Aileen Bayramoglu BAYRAMOGLU LAW OFFICES LLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Chemical preparations for testing blood for medical purposes; Reagents for blood grouping for medical purposes; Solutions for medical use in storing and treating cellsblood and blood components; Medical diagnostic reagents and assays for testing of body fluids; Biological preparations for the treatment of cancer; Diagnostic biomarker reagents for medical purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Mixed biological preparations for the prevention and treatment of infectious diseases; Diagnostic agents and preparations for medical purposes

Publications

History of USPTO decisions and trademark events.

25 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/05/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

11/05/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/20/2024

PUBO

PUBLISHED FOR OPPOSITION

08/20/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/31/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/16/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/16/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/16/2024

ALIE

ASSIGNED TO LIE

07/16/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/26/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/23/2024

GNRT

NON-FINAL ACTION E-MAILED

01/23/2024

CNRT

NON-FINAL ACTION WRITTEN

01/23/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/09/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/08/2024

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

01/08/2024

GNS2

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

10/24/2023

GNSI

INQUIRY TO SUSPENSION E-MAILED

10/24/2023

CNSI

SUSPENSION INQUIRY WRITTEN

10/24/2023

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

04/19/2023

GNSL

LETTER OF SUSPENSION E-MAILED

04/19/2023

CNSL

SUSPENSION LETTER WRITTEN

04/19/2023

DOCK

ASSIGNED TO EXAMINER

04/18/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/25/2022

NWAP

NEW APPLICATION ENTERED

07/08/2022

Continuous trademark protection

Get notified about every new filing that threatens CYTOGEN or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.